Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
A criminal sentence for OxyContin maker Purdue Pharma clears the way for finalizing its settlement
A judge is expected to sentence OxyContin maker Purdue Pharma to forfeit $225 million to the Justice Department on Tuesday, clearing the way for the company to finalize a settlement of thousands of lawsuits it faces over its role in the opioid…
Natco Pharma: A high-margin business or a volatility trap at 10x earnings?
What drives the margins, and can they hold? What is the semaglutide opportunity worth in unit-economic terms? Does the 10x multiple reflect a structural discount or a mispriced opportunity? A business built on windows, not volume Unlike traditional…
3 Air Quality Myths Costing Your Lab Money And Safety
Air quality in life science labs isn't the kind of topic that grabs headlines. It can't compete with breakthrough Alzheimer's treatments or the next‑generation immunotherapies transforming oncology and yet, it's what they hinge on. Behind…
Judge postpones OxyContin-maker Purdue Pharma's sentencing to let opioid victims attend in person
Judge postpones OxyContin-maker Purdue Pharma's sentencing to let opioid victims attend in person AGAINST THE OPIOID CRISIS. AT THE UPPER ROOM FAMILY RESOURCE CENTER IN DERRY, THEIR MISSION HAS ALWAYS BEEN SIMPLE SUPPORT FAMILIES WHO NEED A PLACE…
Judge postpones OxyContin-maker Purdue Pharma's sentencing to let opioid victims attend in person
A judge on Tuesday delayed the criminal sentencing of OxyContin maker Purdue Pharma in order to allow victims to attend the court proceeding in person. U.S. District Judge Madeline Cox Arleo was originally planning to hand down the sentence Tuesday…
Ruffer LLP Has $3.50 Million Stake in Royalty Pharma PLC $RPRX
Ruffer LLP decreased its position in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 30.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional…
Zealand Pharma A/S (OTCMKTS:ZLDPF) Trading Up 8.2% - Should You Buy?
Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report)'s share price was up 8.2% during trading on Tuesday. The company traded as high as $49.35 and last traded at $49.35. Approximately 1,000 shares traded hands during trading, a decline of 78% from…
Stock Market Today: How Will Sensex, Nifty 50 Trade On April 22?
Stock Market Today: The Indian stock market is expected to open lower on Wednesday, following mixed global market cues, amid cautiousness over the US-Iran ceasefire and as the blockade of the Strait of Hormuz continues. The trends on Gift Nifty…
Stock Market Opening Bell: Sensex Falls 0.32%, Nifty 50 Plummets 0.43%
Amid global uncertainty over the US-Iran ceasefire and continued blockade of the Strait of Hormuz, the Indian stock market benchmark indices opened in red on Wednesday, April 22. While the Sensex declined 0.32% to 79,019.34 level, Nifty 50…
Elkedonia strengthens Board of Directors with appointment of Pierre d'Epenoux as Independent Chairman
Appointment strengthens Elkedonia's governance as the company continues its development and prepares for its next phases of growth Pierre d'Epenoux is former CEO of ImCheck Therapeutics, a clinical-stage biotech immuno-oncology company acquired by…
With successful trials, Roche takes its MS drug to regulators, but safety questions loom
The Swiss drugmaker Roche on Tuesday presented the latest data for its experimental multiple sclerosis drug, setting the stage for the company to seek approval for a medicine that it believes can cut relapse rates and slow the progressive…
Prediction: Investors Rotating Out of Artificial Intelligence (AI) Stocks Made a Costly Mistake. The Nasdaq Proves It.
Over the past three years, artificial intelligence (AI) stocks have been the engine driving the stock market higher. Of course, many stocks across industries also gained, but AI stocks offered the biggest push. And for a good reason: AI has the…
AI is spitting out more potential drugs than ever. This start-up wants to figure out which ones matter.
AI's biggest impact in science is Google DeepMind's use of a deep learning model to predict the complex structures of proteins — the molecules that drive virtually every process in living cells. But as AI models continue to spit out more…
Is McKesson Stock Still A High-Conviction Compounder?
McKesson's net earnings increased at an average rate of 14.4% over the previous three years, while its earnings per share (EPS) grew by 19.6% annually in that same period. This 5.2% disparity indicates the additional value management has…
Amneal: A Robust Drug Portfolio Worth Watching, Driving Further Upside Potential (AMRX)
Amneal Pharmaceuticals, Inc. remains a Buy, driven by robust top-line growth, a diversified drug pipeline, and macro demand in key clinical areas. AMRX's FY2025 revenue grew 8% to $3.02B, with positive FY26 guidance and outperformance of Crexont…
Receive a Daily briefing on Pharma Industry News
Get Started